Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record.

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

Pietanza, M. Catherine, Kadota, Kyuichi, Huberman, Kety, Sima, Camelia S., Fiore, John J., Sumner, Dyana K., Travis, William D., Heguy, Adriana, Ginsberg, Michelle S., Holodny, Andrei I., Chan, Timothy A., Rizvi, Naiyer A., Azzoli, Christopher G., Riely, Gregory J., Kris, Mark G., Krug, Lee M. · 2012 · Clinical Cancer Research

Abstract

Purpose: This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer (SCLC). Experimental Design: Patients with disease progression after one or two prior chemotherapy regimens received temozolomide at 75 mg/m2/d for 21 days of a 28-day cycle. The primary endpoint was the overall response rate [ORR; complete response (CR) plus partial response (PR)], which was evaluated separately in sensitive and refractory cohorts. In the available tissue, we assessed O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status by PCR and MGMT expression by immunohistochemistry. Results: Sixty-four patients were accrued: 48 patients in the sensitive cohort and 16 in the refractory group. One CR and 10 PRs were noted in sensitive patients [ORR, 23%; 95% confidence interval (CI), 12%–37%]. Two PRs were seen in the refractory cohort (ORR, 13%; 95% CI, 2%–38%). As second- and third-line treatment, the ORR was 22% (95% CI, 9%–40%) and 19% (95% CI, 7%–36%), respectively. Among patients with target brain lesions, 38% had a CR or PR (95% CI, 14%–68%). Grade ≥3 thrombocytopenia and neutropenia were observed in nine patients (14%). A greater number of cases with methylated MGMT had a response compared to those with unmethylated MGMT (38% vs. 7%; P = 0.08). Conclusion: Temozolomide has activity in relapsed SCLC, particularly for brain metastases. Response to temozolomide may correlate with MGMT methylation in SCLC. Clin Cancer Res; 18(4); 1138–45. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-2059

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 188

Metadata

Authors
Pietanza, M. C., Kadota, K., Huberman, K., Sima, C. S., Fiore, J. J., Sumner, D. K., Travis, W. D., Heguy, A., Ginsberg, M. S., Holodny, A. I., Chan, T. A., Rizvi, N. A., Azzoli, C. G., Riely, G. J., Kris, M. G., & Krug, L. M.
Venue
Clinical Cancer Research
Published
2012-02-14
Volume
18
Issue
4
Pages
1138-1145
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2166392962
Cited by
188
References
0
FWCI
4.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-2059
The paper
Pietanza, M. C., Kadota, K., Huberman, K., Sima, C. S., Fiore, J. J., Sumner, D. K., Travis, W. D., Heguy, A., Ginsberg, M. S., Holodny, A. I., Chan, T. A., Rizvi, N. A., Azzoli, C. G., Riely, G. J., Kris, M. G., & Krug, L. M. (2012). Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-2059

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.